Entries by mercuric

EuropaColon Patients’ Survey on The Unmet Needs of Patients Living with Metastatic Colorectal Cancer

Bowel cancer/CRC patients: Please contribute to an important survey that will help EuropaColon understand how patients cope with a diagnosis of metastatic colorectal cancer. EuropaColon aims to unite patients, caregivers, healthcare professionals, politicians, the media and the public in the fight against digestive cancers. The Organisation works with 43 groups in 32 European countries and has […]

MErCuRIC team from the Università degli Studi di Torino publish in Nature

‘Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth’ by authors Giovanni Germano, Simona Lamba, Giuseppe Rospo, Ludovic Barault, Alessandro Magrì, Federica Maione, Mariangela Russo, Giovanni Crisafulli, Alice Bartolini, Giulia Lerda, Giulia Siravegna, Benedetta Mussolin, Roberta Frapolli, Monica Montone, Federica Morano, Filippo de Braud, Nabil Amirouchene-Angelozzi, Silvia Marsoni, Maurizio D’Incalci, Armando Orlandi, Enrico Giraudo, Andrea Sartore-Bianchi, Salvatore Siena, Filippo Pietrantonio, Federica Di Nicolantonio & Alberto Bardelli was published in Nature and online 29 November 2017.   Abstract: Molecular alterations […]

Two MErCuRIC publications from the Università degli Studi di Torino

Our MErCuRIC partners at the University of Torino (UNITO) have recently published two important papers. One appears in the October 5, 2017, edition of Gut, “Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer.” The second paper titled, “Tracking a CAD-ALK gene rearrangement in urine and blood […]

1st European Alliance for Personalised Medicine Congress

The 1st European Alliance for Personalised Medicine Congress – ‘Forward As One: Making personalised medicine a reality at national level’  is being held 27 – 30 Nov 2017 in Belfast, Northern Ireland. The congress will be interactive, focusing on diseases, general science issues (Big Data, genomics, clinical trials, etc.) and the views, progress and health landscapes across Europe. With […]

Two events in Germany for Patient Advocates and Experts

ESMO Workshop: Science for Advocates Munich – 13 – 15 October 2017 Click here to apply and for further details. Travel grants available in limited number. ‘Science for advocates’ will be a 2-day interactive workshop (Friday afternoon till Sunday lunch-time) with a combination of lectures, independent and group work. To ensure effective communication, the workshop […]

EUPATI’s Latest News

EUPATI as an EPF programme is approaching the end of its first year, and EPF President Marco Greco evaluates the achievements – and challenges – of this new environment and shares his perspectives here. The EUPATI Training Course Patient Experts in Medicines Research & Development has 57 new participants in cohort three. This exciting and unique […]

EUPATI Webinar on Patient Experience in HTA | 26 September 2017, 17:00 to 18:30 CET

Join EUPATI‘s webinar to hear about patients relating their experience when going through Health Technology Assessment (HTA) processes. Two EUPATI Fellows, Paola Kruger (Italy) and Joan Jordan (Ireland) will share their experiences. The point of view of the pharmaceutical industry involved in the HTA process will also be highlighted. Two representatives from Roche, David McCarthy and […]

Hajrah A. Khawaja, QUB will present MErCuRIC research at ESMO in Madrid, September 2017

Hajrah A. Khawaja, a post-graduate student in the School of Medicine, Dentistry and Biomedical Sciences, Centre for Cancer Research and Cell Biology, at Queen’s University of Belfast, UK presents her poster ‘RalB GTPase: A potential novel target for RAS mutant colorectal cancer‘ at the European Society for Medical Oncology conference. ESMO 2017 will be held […]

New publication from UNITO

The UNITO team (D. Oddo et al.) has just published Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer in the British Journal of Cancer (DOI: 10.1038/bjc.2017.196). Background: Combined MET and BRAF inhibition showed clinical benefit in a patient with rectal cancer carrying BRAFV600E and MET amplification. However, after 4 months, acquired […]